Generali Investments CEE investicni spolecnost a.s. Purchases New Position in Cencora, Inc. (NYSE:COR)

Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 910 shares of the company's stock, valued at approximately $253,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $478,309,000. Bank of America Corp DE raised its holdings in Cencora by 62.3% in the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock valued at $1,166,944,000 after acquiring an additional 1,994,256 shares in the last quarter. Castlekeep Investment Advisors LLC bought a new stake in shares of Cencora during the 4th quarter valued at $399,508,000. GAMMA Investing LLC grew its holdings in shares of Cencora by 43,561.9% during the 1st quarter. GAMMA Investing LLC now owns 1,598,461 shares of the company's stock worth $444,516,000 after purchasing an additional 1,594,800 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Cencora by 20.4% in the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock worth $728,757,000 after purchasing an additional 550,246 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer directly owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the sale, the chairman owned 311,913 shares in the company, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,127 shares of company stock worth $9,812,296 in the last ninety days. Insiders own 10.80% of the company's stock.

Analyst Upgrades and Downgrades

COR has been the topic of several analyst reports. Jefferies Financial Group increased their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research report on Monday, June 30th. Bank of America lifted their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Robert W. Baird upped their price objective on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and an average target price of $306.33.

Cencora Trading Up 2.1%

Shares of NYSE:COR traded up $6.20 during mid-day trading on Monday, reaching $302.43. 1,597,776 shares of the company's stock were exchanged, compared to its average volume of 1,507,152. The firm has a market capitalization of $58.62 billion, a price-to-earnings ratio of 35.08, a PEG ratio of 1.47 and a beta of 0.57. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The business's fifty day moving average price is $291.41 and its 200-day moving average price is $268.32. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The business's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.80 EPS. On average, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.73%. Cencora's payout ratio is 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.